Rubin P C, Butters L, Reynolds B, Evans J, Sumner D, Low R A, Reid J L
Br J Clin Pharmacol. 1983 Dec;16(6):659-62. doi: 10.1111/j.1365-2125.1983.tb02237.x.
The elimination of the cardioselective beta-adrenoceptor antagonist atenolol has been studied in 35 neonates by measuring drug concentration in cord blood and in blood obtained at 24 h by heel stab. Elimination rate was assessed by calculating the slopes of lines joining these two concentration points. The slopes had a mean of 0.043 h-1 (equivalent to a half-life of 16 h) and were normally distributed with 95% of values being in the range 0.02-0.066. There was no relationship between slope and neonatal weight or skinfold thickness, but most babies were at term and the range of these indices was narrow. Babies who developed a bradycardia had cord atenolol concentrations and slopes which did not differ significantly from those in babies without bradycardia. We conclude that atenolol elimination in the neonate is reduced when compared to adults. This prolonged elimination is consistent with the physiological characteristics of this age group and with previous observations on drugs eliminated by renal excretion.
通过测量脐血以及出生24小时足跟穿刺采血中的药物浓度，对35名新生儿使用心脏选择性β肾上腺素能受体拮抗剂阿替洛尔的消除情况进行了研究。通过计算连接这两个浓度点的直线斜率来评估消除率。斜率的平均值为0.043 h⁻¹（相当于半衰期为16小时），呈正态分布，95%的值在0.02 - 0.066范围内。斜率与新生儿体重或皮褶厚度之间没有关系，但大多数婴儿为足月儿，这些指标的范围较窄。出现心动过缓的婴儿，其脐血阿替洛尔浓度和斜率与未出现心动过缓的婴儿相比，差异无统计学意义。我们得出结论，与成年人相比，新生儿阿替洛尔的消除减慢。这种消除时间的延长与该年龄组的生理特征以及先前关于经肾排泄消除的药物的观察结果一致。
